Recap: Oncternal Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Oncternal Therapeutics (NASDAQ:ONCT) reported Q4 earnings with an EPS of $-3.11, missing estimates by -1.0% against an expected $-3.07. Revenue increased by $126 thousand year-over-year. The company's past earnings performance shows a pattern of missing EPS estimates, which previously led to a 3.0% drop in share price the following day.
March 07, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Oncternal Therapeutics reported a Q4 EPS of $-3.11, missing estimates by -1.0%, with a year-over-year revenue increase of $126 thousand.
Given Oncternal Therapeutics' history of missing EPS estimates and the subsequent negative impact on its share price, as evidenced by a 3.0% drop following last quarter's earnings miss, it's likely that this earnings miss could lead to a short-term negative impact on ONCT's stock price. The pattern of missing estimates and the historical reaction in the share price suggest a potential repeat of this trend.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100